4 janvier 2013 Société Française d’Hypertension Artérielle - www. sfhta.org
AlKhalaf MM,ThalibL, DoiSA. Cardiovascularoutcomesinhigh-riskpatientswithoutheartfailure
treatedwithARBs:asystematicreviewandmeta-analysis.AmJCardiovascDrugs2009;9(1):29-43.
BakerWL,ColemanCI,KlugerJ,etal.Systematicreview:comparativeeffectivenessofangiotensin-
convertingenzymeinhibitorsorangiotensinII-receptorblockersforischemicheartdisease.AnnIntern
Med2009;151(12):861-71.
BalamuthusamyS,SrinivasanL,VermaM,etal.Reninangiotensinsystemblockadeandcardiovas-
cularoutcomesinpatientswithchronickidneydiseaseandproteinuria:ameta-analysis.AmHeartJ
2008;155(5):791-805.
Bangalore S, Kumar S, Lobach I. Blood pressure targets in subjects with type 2 diabetes mellitus/
impairedfastingglucose:observationsfromtraditionalandbayesianrandom-effectsmeta-analysesof
randomizedtrials.Circulation201121;123:2799-810.
Bangalore S, Kumar S, Wetterslev J.Angiotensin receptor blockers and risk of myocardial infarc-
tion: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ
2011;342:d2234.
BarolettiSteven,HeatherDell’Orfano.MedicationAdherenceinCardiovascularDisease.Circulation.
2010;121:1455-1458.
Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80
yearsand older: thelower thebetter?Ameta-analysis ofrandomized controlled trials.J Hypertens
2010;28(7):1366-72.
BloodPressureLoweringTreatmentTrialists’Collaboration,TurnbullF,NealB,NinomiyaT,AlgertC,
ArimaH,etal.Effectsofdifferentregimenstolowerbloodpressureonmajorcardiovasculareventsin
olderandyoungeradults:meta-analysisofrandomisedtrials.BMJ2008;336(7653):1121-3.
BramlageP,HasfordJ.Bloodpressurereduction,persistenceandcostsintheevaluationofantihyper-
tensivedrugtreatment--areview.CardiovascDiabetol2009;8:18.
Chen JM, Heran BS, Perez MI. Blood pressure lowering efcacy of beta-blockers as second-line
therapy for primary hypertension. The Cochrane Database of Systematics Reviews 2010;Issue
1:CD007185.
ChobanianAV,Bakris GL,Black HR, etal. National Heart,Lung, andBloodInstitute JointNational
CommitteeonPrevention,Detection,Evaluation,andTreatmentofHighBloodPressure;NationalHigh
BloodPressureEducationProgramCoordinatingCommittee.TheSeventhReportoftheJointNational
CommitteeonPrevention,Detection,Evaluation,andTreatmentofHighBloodPressure:theJNC7
report.JAMA2003;289:2560-72.
CostaFV,D’AusilioA, BianchiC.Adherenceto antihypertensivemedication :areviewandupdate.
Highbloodpressureandcardiovascularprevention2009;16(3):101-10.
Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular out-
comes:ameta-analysisof175,634patients.JHypertens2009;27(6):1136-51.
DanchinN,CucheratM,ThuillezC.Angiotensin-convertingenzymeinhibitorsinpatientswithcoronary
arterydiseaseandabsenceofheartfailureorleftventricularsystolicdysfunction:anoverviewoflong-
termrandomizedcontrolledtrials.ArchInternMed2006;166(7):787-96.
DaskalopoulouSS,KhanNA,QuinnRR;CanadianHypertensionEducationProgram.The2012Ca-
nadianhypertensioneducationprogramrecommendationsforthemanagementofhypertension:blood
pressuremeasurement,diagnosis,assessmentofrisk,andtherapy.CanJCardiol2012;28:270-87.
EganBM,ZhaoY,AxonRN.UStrendsinprevalence,awareness,treatment,andcontrolofhyperten-
sion,1988-2008.JAMA2010;303:2043-50.
FeldmanRD,ZouGY,VandervoortMK.Asimpliedapproachtothetreatmentofuncomplicatedhyper-
tension:aclusterrandomized,controlledtrial.Hypertension.2009Apr;53(4):646-53.Epub2009Feb
23.
GuptaAK,ArshadS,PoulterNR.Compliance,safety,andeffectivenessofxed-dosecombinationsof
antihypertensiveagents:ameta-analysis.Hypertension2010;55(2):399-407.
HackamDG,KhanNA,HemmelgarnBR.CanadianHypertensionEducationProgram.The2010Ca-
nadianHypertensionEducationProgramrecommendationsforthemanagementofhypertension:part
2-therapy.CanJCardiol.2010;26:249-58.
HAS,HauteAutoritédeSanté:Priseenchargedespatientsadultesatteintsd’hypertensionartérielle
essentielle.2005,HauteAutoritédeSanté.
KronishIM,WoodwardM,SergieZ.Meta-Analysis:ImpactofDrugClassonAdherencetoAntihyper-
tensives.Circulation2011,123:1611-1621.
LawMR,MorrisJK,WaldNJ.Useofbloodpressureloweringdrugsinthepreventionofcardiovascular
disease:meta-analysisof147randomisedtrialsinthecontextofexpectationsfromprospectiveepide-
miologicalstudies.BMJ2009;338:b1665.
ManciaG,DeBackerG,DominiczakA,etal.ManagementofArterialHypertensionoftheEuropean
Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of
Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the Euro-
peanSocietyofHypertension(ESH)andoftheEuropeanSocietyofCardiology(ESC).JHypertens
2007;25:1105-87.
ManciaG,LaurentS,Agabiti-RoseiE;EuropeanSocietyofHypertension.ReappraisalofEuropean
guidelinesonhypertensionmanagement:aEuropeanSocietyofHypertensionTaskForcedocument.
JHypertens2009;27:2121-58.
McGuinnessB,ToddS,PassmoreP,BullockR.Bloodpressureloweringinpatientswithoutpriorcere-
brovasculardiseaseforpreventionofcognitiveimpairmentanddementia.TheCochraneDatabaseof
SystematicsReviews2009;Issue4:CD004034.
MusiniVM,TejaniAM,BassettK,WrightJM. Pharmacotherapyfor hypertensionin theelderly.The
CochraneDatabaseofSystematicsReviews2009;Issue4.
NationalCollaboratingCentreforChronicConditions.Hypertension:managementinadultsinprimary
care : pharmacological update. London: Royal College of Physicians; british Hypertension Society;
2006.
NavaneethanSD,NigwekarSU,SehgalAR,StrippoliGF.Aldosteroneantagonistsforpreventingthe
progressionofchronickidneydisease:asystematicreviewandmeta-analysis.ClinJAmSocNephrol
2009;4(3):542-51.
ReboldiG,AngeliF,CavalliniC.Comparisonbetweenangiotensin-convertingenzymeinhibitorsand
angiotensinreceptorblockersontheriskofmyocardialinfarction,strokeanddeath:ameta-analysis.
JHypertens2008;26:1282-9.
ReboldiG,GentileG,AngeliF.Effectsofintensivebloodpressurereductiononmyocardialinfarction
andstrokeindiabetes:ameta-analysisin73,913patients.JHypertens2011;29:1253-69.
RecommandationsduNICE2011.http://www.nice.org.uk/nicemedia/live/12167/53228/53228.pdf.
SaradisPA, StafylasPC,KanakiAI,LasaridisAN.Effectsofrenin-angiotensin systemblockerson
renaloutcomesandall-causemortalityinpatientswithdiabeticnephropathy:Anupdatedmeta-analy-
sis.AmJHypertens2008;21(8):922-9.
Sciarretta S, Palano F, Tocci G. Antihypertensive Treatment and Development of Heart Failure in
Hypertension:ABayesianNetworkMeta-analysisofStudiesinPatientsWithHypertensionandHigh
CardiovascularRisk.ArchInternMed2010.
StaessenJA,RichartT,WangZ.ImplicationsofRecentlyPublishedTrialsofBloodPressure-Lowering
DrugsinHypertensiveorHigh-RiskPatients.Hypertension.2010;55:819-831.
VrijensBernard,GäborVincze,PaulusKristanto,Adherencetoprescribedantihypertensivedrugtreat-
ments:longitudinalstudyofelectronicallycompileddosinghistories.BMJ.2008May17;336(7653):
1114–1117.
WeberMA,BakrisGL,JamersonK,etal.Cardiovasculareventsduringdifferinghypertensionthera-
piesinpatientswithdiabetes.JAmCollCardiol2010;56(1):77-85.
WetzelsGE,NelemansP,SchoutenJS.Factsandctionofpoorcomplianceasacauseofinadequate
bloodpressurecontrol:asystematicreview.JHypertens2004;22(10):1849-55.
WiysongeCS,BradleyH,MayosiBM,etal.Beta-blockersforhypertension.TheCochraneDatabase
ofSystematicsReviews2007;Issue1:CD002003.
Wright JM, Musini VM. First-line drugs for hypertension. The Cochrane Database of Systematics
Reviews2009;Issue3.
ZanchettiA.Bottombloodpressureorbottomcardiovascularrisk?Howfarcancardiovascularriskbe
reduced?JournalofHypertension2009,27:1509–1520
ZhangY,ZhangP,MuY,etal.TheRoleofRenin-AngiotensinSystemBlockadeTherapyinthePreven-
tionofAtrialFibrillation:AMeta-AnalysisofRandomizedControlledTrials.ClinPharmacolTher2010.
RÉFÉRENCES
Les signataires de ce document indiquent avoir des liens d’intérêt avec des industriels qui commercialisent des produits de santé.
Ils déclarent avoir réalisé ces recommandations en toute indépendance.
Pourlaréalisationdecetterecommandation,lesrèglessuivantesontétéappliquées:
- Favoriserl’utilitépourlapratiquequotidiennedelapriseenchargedel’HTA.
- Fournirsousuneformesynthétiquelesrecommandationsetlimiterlenombredepagesdudocument.
- RendrelarédactionintelligibleauxsujetstraitéspouruneHTAandefavoriserl’observanceauxtraitementsdespatients.
- Promouvoirl’éducationthérapeutiqueetl’adhésionaulongcoursàlapriseenchargedel’HTA.
- Utiliserlestravauxderecherchebibliographiqueréalisésparlesauteursdesrecommandationspréalables,etprendreenconsidérationuniquementles
revuessystématiques,lesconférencesdeconsensus,lesméta-analysesetlesrecommandationsnationalesouinternationalespubliéescesdernières
années.Nepasdonnerunpoidsinadaptéauxessaisthérapeutiquesrécentsouauxrésultatstroplargementmédiatisés.
- S’abstenird’émettreunerecommandationsurunethématiqueayantunniveaudepreuvetropfaible.
- Andepromouvoircetterecommandationauprèsdesprofessionnelsdesanté,unpartenariataveclaHauteAutoritédeSanté,aveclaCaisseNationale
d’AssuranceMaladieetavecl’institutNationaldePréventionetd’EducationàlaSantéseraproposé.Ilestsouhaitéunelargediffusiondecedocument
auprèsdesmédecinsprenantenchargel’HTA,maisaussiauprèsdesautresprofessionnelsdesanté(pharmaciens,inrmiers).
- Uneévaluationdel’impactdelarecommandationsurlesobjectifsdesantépublique,baséesurlaréalisationd’uneenquêteépidémiologiquesurun
échantillonreprésentatifdelapopulationvivantenFranceettraitéepourHTA,seraàorganiseraprèssadiffusion.
RECOMMANDATION
Société Française
d’HyperTension Artérielle